Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Histoplasmosis may complicate tumor necrosis factor (TNF)-α blocker therapy. Published case series provide limited guidance on disease management. We sought to determine the need for long-term antifungal therapy and the safety of resuming TNF-α blocker therapy after successful treatment of histoplasmosis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Infect. Dis.

Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1537-6591

ISSN (Print): 1058-4838

Publication date (Electronic): Aug 01 2015

Volume: 61

Issue: 3

Affiliations

[1 ] Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania.

[2 ] Division of Infectious Disease, Johns Hopkins Hospital, Baltimore, Maryland.

[3 ] MiraVista Diagnostics and Mirabella Technologies, Indianapolis, Indiana.

[4 ] Division of Pediatric Gastroenterology, Hepatology and Nutrition, and Center for Innovation in Pediatric Practice, The Research Institute, Nationwide Children's Hospital, Columbus, Ohio.

[5 ] Department of Internal Medicine, University of Kansas School of Medicine, Wichita.

[6 ] Division of Infectious Diseases, University of Kansas Medical Center, Kansas City.

[7 ] Division of Infectious Disease, Wright State University Boonshoft School of Medicine, Dayton, Ohio.

[8 ] Division of Infectious Diseases, University of Nebraska Medical Center, Omaha.

[9 ] Infectious Disease Associates of Kansas City, Missouri.

[10 ] Department of Medicine, Meritus Medical Center, Hagerstown, Maryland.

[11 ] Division of Infectious Disease, University of Kentucky, Lexington.

[12 ] Department of Medicine and Medical Microbiology and Immunology, University of Wisconsin, Madison.

[13 ] Long Island Infectious Disease Associates, Huntington, New York.

[14 ] Division of Infectious Disease, University of Michigan Medical School, Ann Arbor.

[15 ] Division of Infectious Diseases, Kaiser Permanente, Fontana, California.

[16 ] Ellis Hospital Schenectady, New York.

[17 ] Division of Infectious Diseases, University of Iowa, Iowa City.

[18 ] Samaritan Infectious Disease, Corvallis, Oregon.

[19 ] Division of Infectious Diseases, Southern Illinois University School of Medicine, Springfield.

[20 ] Indiana University Health Ball Memorial Hospital, Muncie.

[21 ] Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.

[22 ] Pulmonary-Critical Care Medicine, Indiana University, Indianapolis.

Article

Publisher Item ID: civ299

DOI: 10.1093/cid/civ299

PMC ID: 4796723

PubMed ID: 25870331

SO-VID: 8eaf041a-5058-496a-95f5-ed79dffe334e

History

Keywords: adalimumab,etanercept,histoplasmosis,immune reconstitution syndrome,infliximab

Data availability:

Keywords: adalimumab, etanercept, histoplasmosis, immune reconstitution syndrome, infliximab

Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

Read this article at

Abstract

Related collections

Negative Pressure Wound Therapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 506

Cited by 41